SOPHiA GENETICS was founded in 2011 to shape the future of clinical genomics. Today, the company’s artificial intelligence is used to better and faster diagnose patients worldwide. Through its SaaS platform SOPHiA has connected hundreds of hospitals across 60 countries, enabling clinicians around the world to collaborate, and find better treatment options for their patients. The company is experiencing exponential growth and is investing heavily to further develop its technology and expand in new markets.
Alychlo has been an important investor in SOPHiA since 2015.
For more information: www.sophiagenetics.com